Maarit Tarkiainen1, Pirjo Tynjälä2, Paula Vähäsalo3, Pekka Lahdenne4. 1. Children's Hospital, Helsinki University Central Hospital, Institute of Clinical Medicine, University of Helsinki, Poison Information Center, Helsinki University Central Hospital, Helsinki, Finland, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland Children's Hospital, Helsinki University Central Hospital, Institute of Clinical Medicine, University of Helsinki, Poison Information Center, Helsinki University Central Hospital, Helsinki, Finland, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland maarit.tarkiainen@helsinki.fi. 2. Children's Hospital, Helsinki University Central Hospital, Institute of Clinical Medicine, University of Helsinki, Poison Information Center, Helsinki University Central Hospital, Helsinki, Finland, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland Children's Hospital, Helsinki University Central Hospital, Institute of Clinical Medicine, University of Helsinki, Poison Information Center, Helsinki University Central Hospital, Helsinki, Finland, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland. 3. Children's Hospital, Helsinki University Central Hospital, Institute of Clinical Medicine, University of Helsinki, Poison Information Center, Helsinki University Central Hospital, Helsinki, Finland, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland Children's Hospital, Helsinki University Central Hospital, Institute of Clinical Medicine, University of Helsinki, Poison Information Center, Helsinki University Central Hospital, Helsinki, Finland, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland Children's Hospital, Helsinki University Central Hospital, Institute of Clinical Medicine, University of Helsinki, Poison Information Center, Helsinki University Central Hospital, Helsinki, Finland, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland. 4. Children's Hospital, Helsinki University Central Hospital, Institute of Clinical Medicine, University of Helsinki, Poison Information Center, Helsinki University Central Hospital, Helsinki, Finland, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland.
Abstract
OBJECTIVE: The aim of this study was to carry out a safety evaluation of biologic agents in patients with JIA and associated uveitis. METHODS: In three tertiary centres in Finland, all adverse events (AEs) in 348 consecutive patients were collected. AEs were classified according to the Common Terminology Criteria for AEs. RESULTS: A total of 1516 patient-years (py) were included: 710 on etanercept, 591 on infliximab, 188 on adalimumab, 8 on rituximab, 5 on anakinra, 6 on tocilizumab, 6 on abatacept and 1 on golimumab. The median follow-up of an individual patient was 51 months (range 1-155). The most common of the 2902 AEs (191/100 py) observed were mild infections, infusion or injection site reactions and alanine aminotransferase elevations. At least one AE occurred in 319 (92%) patients and 121 (35%) had at least one serious AE (SAE). The rate of SAEs was 11.4/100 py on etanercept, 11.8 on infliximab, 10.1 on adalimumab, 15.7 on abatacept, 31.2 on tocilizumab and 87.5 on rituximab, higher than with most anti-TNF agents (P = 0.005). No cases of malignant neoplasms or tuberculosis were detected. New-onset uveitis occurred in 9 patients, psoriasis or psoriasiform lesions in 13 and IBD in 6. CONCLUSION: Mild and moderate AEs in patients with JIA treated with biologics were more frequent than previously reported. SAEs were observed in one-third of the patients, but SAEs seldom led to drug discontinuation.
OBJECTIVE: The aim of this study was to carry out a safety evaluation of biologic agents in patients with JIA and associated uveitis. METHODS: In three tertiary centres in Finland, all adverse events (AEs) in 348 consecutive patients were collected. AEs were classified according to the Common Terminology Criteria for AEs. RESULTS: A total of 1516 patient-years (py) were included: 710 on etanercept, 591 on infliximab, 188 on adalimumab, 8 on rituximab, 5 on anakinra, 6 on tocilizumab, 6 on abatacept and 1 on golimumab. The median follow-up of an individual patient was 51 months (range 1-155). The most common of the 2902 AEs (191/100 py) observed were mild infections, infusion or injection site reactions and alanine aminotransferase elevations. At least one AE occurred in 319 (92%) patients and 121 (35%) had at least one serious AE (SAE). The rate of SAEs was 11.4/100 py on etanercept, 11.8 on infliximab, 10.1 on adalimumab, 15.7 on abatacept, 31.2 on tocilizumab and 87.5 on rituximab, higher than with most anti-TNF agents (P = 0.005). No cases of malignant neoplasms or tuberculosis were detected. New-onset uveitis occurred in 9 patients, psoriasis or psoriasiform lesions in 13 and IBD in 6. CONCLUSION: Mild and moderate AEs in patients with JIA treated with biologics were more frequent than previously reported. SAEs were observed in one-third of the patients, but SAEs seldom led to drug discontinuation.
Authors: Jasper F M M Rieter; Laura Tanturri de Horatio; Charlotte M Nusman; Lil-Sofie Ording Müller; Robert Hemke; Derk F M Avenarius; Marion A J van Rossum; Clara Malattia; Mario Maas; Karen Rosendahl Journal: Pediatr Radiol Date: 2016-07-12
Authors: Sarah Ringold; Sheila T Angeles-Han; Timothy Beukelman; Daniel Lovell; Carlos A Cuello; Mara L Becker; Robert A Colbert; Brian M Feldman; Polly J Ferguson; Harry Gewanter; Jaime Guzman; Jennifer Horonjeff; Peter A Nigrovic; Michael J Ombrello; Murray H Passo; Matthew L Stoll; C Egla Rabinovich; Rayfel Schneider; Olha Halyabar; Kimberly Hays; Amit Aakash Shah; Nancy Sullivan; Ann Marie Szymanski; Marat Turgunbaev; Amy Turner; James Reston Journal: Arthritis Care Res (Hoboken) Date: 2019-04-25 Impact factor: 4.794
Authors: Sarah Ringold; Sheila T Angeles-Han; Timothy Beukelman; Daniel Lovell; Carlos A Cuello; Mara L Becker; Robert A Colbert; Brian M Feldman; Polly J Ferguson; Harry Gewanter; Jaime Guzman; Jennifer Horonjeff; Peter A Nigrovic; Michael J Ombrello; Murray H Passo; Matthew L Stoll; C Egla Rabinovich; Rayfel Schneider; Olha Halyabar; Kimberly Hays; Amit Aakash Shah; Nancy Sullivan; Ann Marie Szymanski; Marat Turgunbaev; Amy Turner; James Reston Journal: Arthritis Rheumatol Date: 2019-04-25 Impact factor: 10.995
Authors: Päivi H Salonen; Juha H Salonen; Hanna Säilä; Mika Helminen; Miika Linna; Markku J Kauppi Journal: Clin Rheumatol Date: 2019-11-16 Impact factor: 2.980
Authors: Megan L Krause; Jorge A Zamora-Legoff; Cynthia S Crowson; Theresa Wampler Muskardin; Thomas Mason; Eric L Matteson Journal: Semin Arthritis Rheum Date: 2016-07-18 Impact factor: 5.532
Authors: Jorge A Zamora-Legoff; Megan L Krause; Cynthia S Crowson; Theresa Wampler Muskardin; Thomas Mason; Eric L Matteson Journal: Clin Rheumatol Date: 2016-01-29 Impact factor: 2.980